Becton Dickinson and (NYSE:BDX) had its price target decreased by Piper Jaffray Companies to $250.00 in a report released on Tuesday, The Fly reports. Piper Jaffray Companies currently has an overweight rating on the medical instruments supplier’s stock. Piper Jaffray Companies also issued estimates for Becton Dickinson and’s Q1 2019 earnings at $2.79 EPS, Q2 2019 earnings at $2.90 EPS, Q3 2019 earnings at $3.07 EPS, Q4 2019 earnings at $3.33 EPS, FY2019 earnings at $12.10 EPS, Q1 2020 earnings at $3.17 EPS, Q2 2020 earnings at $3.42 EPS, Q3 2020 earnings at $3.67 EPS, Q4 2020 earnings at $3.68 EPS and FY2020 earnings at $13.94 EPS.

Several other research analysts also recently commented on BDX. Morgan Stanley raised their price target on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an equal weight rating in a report on Thursday, October 4th. Wells Fargo & Co raised their price target on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an outperform rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Barclays started coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They issued an equal weight rating and a $278.00 price target for the company. Royal Bank of Canada reissued a hold rating and issued a $248.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, KeyCorp reissued a buy rating and issued a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $254.07.

BDX traded down $1.22 on Tuesday, hitting $243.26. The company’s stock had a trading volume of 1,005,699 shares, compared to its average volume of 1,421,737. The company has a market cap of $63.38 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.46 and a beta of 1.19. Becton Dickinson and has a 12 month low of $209.91 and a 12 month high of $265.87. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. The company had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. Becton Dickinson and’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same period last year, the firm earned $2.40 EPS. Research analysts forecast that Becton Dickinson and will post 12.2 earnings per share for the current fiscal year.

In other news, Director Timothy M. Ring sold 42,000 shares of the firm’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the sale, the director now owns 93,688 shares in the company, valued at approximately $22,210,614.16. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP James C. Lim sold 5,189 shares of the firm’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the sale, the executive vice president now owns 13,318 shares in the company, valued at approximately $3,227,750.48. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in Becton Dickinson and by 1.3% in the 3rd quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock worth $4,966,582,000 after purchasing an additional 253,041 shares during the period. FMR LLC raised its position in Becton Dickinson and by 8.0% in the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock worth $4,529,401,000 after purchasing an additional 1,286,579 shares during the period. Fundsmith Equity Fund L.P. purchased a new position in Becton Dickinson and in the 2nd quarter worth $894,775,000. Wells Fargo & Company MN raised its position in Becton Dickinson and by 0.8% in the 3rd quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock worth $930,491,000 after purchasing an additional 27,188 shares during the period. Finally, Putnam Investments LLC raised its position in Becton Dickinson and by 0.5% in the 2nd quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock worth $841,690,000 after purchasing an additional 18,859 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

See Also: Cost of Debt

The Fly

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.